The #1 Biotech Misconception About Market Access: “A Partner Will Handle It”
“We don’t need to worry about Market Access, once we find a partner, they’ll take
“We don’t need to worry about Market Access, once we find a partner, they’ll take
In less than twelve months, the Trump administration turned a contested policy idea into a
December 2025 marked a defining moment in U.S. drug pricing and Medicare reimbursement policy. Alongside
December 2025 marked a pivotal moment in U.S. drug pricing policy. The Global Benchmark for
Most Favoured Nation (MFN) pricing policies are increasingly shaping global pharmaceutical launch, pricing, and access
What began as “Most Favored Nation” (MFN) concepts has now materialized into concrete policy mechanisms.